Text Size

Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2005 by University Health Network, Toronto.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00327639
First received: May 17, 2006
Last updated: NA
Last verified: July 2005
History: No changes posted
  Purpose

Treatment of patients with beta thalassemia in North America has altered dramatically during the past 40 years, with improvements in transfusion therapy and introduction of iron chelation therapy. Thalassemia patients now enjoy an increased life expectancy to the fifth and sixth decades of life, with fertility and childbearing becoming important issues. Data regarding this important topic remain limited, without clear data regarding iron control including serial assessment of hepatic iron concentration, the need for assistance in becoming pregnant, and use of iron chelating agents during pregnancy. As the life expectancy increases and overall health improves in thalassemia, clear data on fertility, pregnancy complications, and the effect of pregnancy on maternal health in thalassemia patients are necessary since these will have a direct impact on patient care, quality of life, and patient expectations.


Condition
Thalassemia
Fertility
Pregnancy

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Retrospective/Prospective
Official Title: Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto

Resource links provided by NLM:

MedlinePlus related topics: Iron Thalassemia
U.S. FDA Resources

Further study details as provided by University Health Network, Toronto:

Estimated Enrollment: 50
Study Start Date: July 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Thalassemia, thalassemia intermedia or E-thalassemia patients in Toronto
  • Subject has attempted conception

Exclusion Criteria:

  • Subject has any other form of blood disease
  • Subject has not attempted conception
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00327639

Contacts
Contact: Anthony Apostoli, B.Sc. 416-340-4800 ext 6069 Anthony.Apostoli@uhn.on.ca

Locations
Canada, Ontario
University Health Network, Toronto General Hospital Recruiting
Toronto, Ontario, Canada, M5G 2C4
Contact: Valerie M Joseph     416-340-4800 ext 6507     Valerie.Joseph@uhn.on.ca    
Sponsors and Collaborators
University Health Network, Toronto
Investigators
Principal Investigator: Nancy F Olivieri, MD University Health Network, Toronto General Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00327639     History of Changes
Other Study ID Numbers: 00000
Study First Received: May 17, 2006
Last Updated: May 17, 2006
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Thalassemia
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
 Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on June 18, 2013